Rafael Holdings and Cyclo Therapeutics enter merger deal
Rafael Holdings has signed a definitive merger agreement with Cyclo Therapeutics, aiming to enhance the development of Trappsol Cyclo, a…
Rafael Holdings has signed a definitive merger agreement with Cyclo Therapeutics, aiming to enhance the development of Trappsol Cyclo, a…
Three years after an arimoclomol approval application was rejected, a US Food and Drug Administration (FDA) Genetic Metabolic Diseases Advisory…
The US Food and Drug Administration (FDA) has granted ConSynance Therapeutics a rare paediatric disease designation for its oral therapy…
As increasing varieties of drugs aimed at weight loss hit the shelves, a new treatment that targets obesity and hunger…
Shionogi has concluded an exclusive global licence agreement for Maze Therapeutics’s MZE001, an oral glycogen synthase 1 (GYS1) inhibitor to…
Zydus Lifesciences subsidiary Sentynl Therapeutics has announced the worldwide acquisition of the Zokinvy (lonafarnib) programme from Eiger BioPharmaceuticals for the…
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved TMC Pharma's fosdenopterin (Nulibry) for the treatment of molybdenum…
Biotechnology company Diagonal Therapeutics has announced its launch, raising $128m through a Series A financing round for its new approach…
The US Food and Drug Administration (FDA) has granted approval to Orchard Therapeutics' Lenmeldy (atidarsagene autotemcel) gene therapy for use…
Sionna Therapeutics has continued raising capital, closing a $182m Series C financing round to help advance additional cystic fibrosis candidates…